Possible Skin Cancer Vaccine Shows Promise In Late Stage Trial. Moderna Stock Skyrockets. The late-stage clinical trial was described as a "landmark moment." International Business Times · Aug 19
Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are… The Economic Times · Aug 19
Stocks Mixed on Lower Bond Yields and Chip Stock Weakness The S&P 500 Index ($SPX ) (SPY ) is up by +0.33% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.33%. E-mini S&P futures (ESU26 ) are up +0.31%, and September E-mini... Barchart · Aug 19
Skin cancer vaccine shows promise in preventing recurrence of melanoma in large trial IN FULL The Independent UK · Aug 19
US stocks: US market regains ground as bond yields ease; healthcare stocks rally Major stock indexes recovered on Wednesday after a prior day's decline. Moderna shares surged significantly following positive cancer therapy trial results. Government bond yields eased from highs, boosting investor risk appetite. Retailers like Target and Lowe's reported quarterly results, influencing consumer spending views. Geopolitical developments and Federal Reserve minutes remained… The Economic Times · Aug 19
Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning More than 8,500 Americans are expected to die of melanoma this year The Independent UK · Aug 19
Moderna Begins First Human Trial of a Vaccine for the Ebola Strain Driving Congo's Outbreak Moderna started a phase 1 trial of an mRNA vaccine against Bundibugyo ebolavirus, a strain for which no vaccine is approved, that is driving an outbreak in Congo. Medical Daily · Aug 13
The First mRNA Flu Vaccine Is Approved, and What Changes for Patients Is Not Simply Another Shot Option The FDA approved mFlusiva for adults 50 and older. Here is who qualifies, how mRNA flu shots differ, and what still stands before they become widely available. Medical Daily · Aug 10
FDA Approves First mRNA Flu Shot for Adults 50 and Older Ahead of the 2026–2027 Season FDA approved mFLUSIVA, the first mRNA flu vaccine, for adults 50 and older. Here is what it means for fall shots, timing, and access. Medical Daily · Aug 7
First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often… The Conversation · Aug 6
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out! Barchart · Aug 6
FDA approves first mRNA vaccine for seasonal flu The Food and Drug Administration's approval of an mRNA vaccine for flu comes after the agency initially refused to review the approval request for the shot. LiveScience · Aug 6
First mRNA-based flu shot approved in US - despite RFK Jr’s objections to the science Health Secretary Robert F. Kennedy Jr pulled $500 million in funding for mRNA vaccine development last year - the medical community said the U.S. would pay the price in dollars and lives The Independent UK · Aug 6
New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic The Independent UK · Aug 6
Euronews · Aug 5 Moderna starts human trials for Bundibugyo Ebola vaccine as Congo's outbreak continues Moderna has vaccinated the first participants in a trial for a Bundibugyo Ebola vaccine, as the Democratic Republic of Congo continues to battle its fastest-growing outbreak on record.
Medical Daily · Aug 5 Moderna Says Its Norovirus Vaccine Missed an Early Success Threshold, and the Trial Will Continue Moderna's norovirus vaccine did not meet interim success criteria in phase 3. The trial continues blinded with a new cohort. Here is what that means.
Barchart · Aug 5 Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink? Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.
Medical Daily · Aug 4 The First Vaccine Built for This Ebola Strain Has Entered Human Testing as the DRC Outbreak Becomes the Country's Largest Oxford launched the first Phase 1 trial of a Bundibugyo Ebola vaccine. Licensed Ebola vaccines target a different species and do not cover this strain.
Barchart · Jul 23 Earnings Preview: What To Expect From Moderna’s Report Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.
MarketBeat · Jul 1 Short Squeeze Alert—Moderna Stock Surges on New Strategy Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.
Barchart · Jun 29 MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.
Kiplinger · Jun 26 Stocks Struggle After OpenAI IPO Blow: Stock Market Today Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
The Economic Times · Jun 26 US stocks: US market ends lower as tech stocks weigh on sentiment Wall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies surged. Investors are weighing the long-term potential of AI against concerns about the substantial investment required for data centers. Inflationary pressures, fueled by energy prices and chip costs, remain a…
Medical Daily · Jun 25 FDA Panel Backs Moderna's First mRNA Flu Shot — What It Could Mean for Your Fall Vaccine FDA advisers unanimously backed Moderna's mRNA flu vaccine mFlusiva on June 18. Here's what the 9-0 vote means for fall 2026 vaccination and who it would cover.
AAP · Jun 18 FDA panel backs first-of-its-kind flu vaccine using mRNA technology A new kind of flu vaccine is moving a step closer to the U.S. market